Results
This is a permanent results page for your analyzed data.
Please save the link in your browser's address bar.
SOFT file
| Title / Description |
Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance |
| Accession |
GSE41168
|
| Summary |
Resveratrol has been reported to improve metabolic function in metabolically-abnormal rodents and humans, but has not been studied in non-obese people with normal glucose tolerance. We conducted a randomized, double-blind, placebo-controlled trial to evaluate the metabolic effects of 12 weeks of resveratrol supplementation (75 mg/day) in non-obese, postmenopausal women with normal glucose tolerance. Although resveratrol supplementation was well-tolerated and increased plasma resveratrol concentration without adverse effects, it did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers. A two-stage hyperinsulinemic-euglycemic clamp procedure, in conjunction with stable isotopically-labeled tracer infusions, demonstrated that resveratrol did not increase liver, skeletal muscle, or adipose tissue insulin sensitivity. Consistent with the absence of in vivo metabolic effects, resveratrol did not affect its putative molecular targets, including AMPK, Sirt1, Nampt, and Pgc-1α, in either skeletal muscle or adipose tissue. These findings demonstrate that resveratrol supplementation does not have metabolic effects in non-obese women. |
| Organism |
Homo sapiens |
| Platform |
GPL570 |
| Normalized |
False |
| Parsed SOFT file |
|
Metadata
| Differential expression method |
Characteristic Direction
|
| Cutoff |
500 |
| Drug_name |
resveratrol |
| Smiles |
Oc1ccc(cc1)/C=C/c1cc(O)cc(c1)O |
| Drugbank_id |
DB02709 |
| Cell_type |
Adipose |
| Organism |
human |
Visualizations
| Principal Component Analysis |
|
| Hierarchical clustering |
|
External Links and Downloads
|
Gene lists
|
Enrichr
|
L1000CDS2
|
PAEA
|
Crowdsourcing |
| Up |
|
|
|
|
|
| Down |
|
|
|
|
|
| Combined |
|
|
|
|
|
